Investor Presentaiton

Guardant360 in lung cancer Diagnosis with metastatic CD74-ROS1- positive lung cancer Entrectinib dose escalation (800 mg) Progression in brain Progression in brain and bones I Detection of ROS1 F2004V resistance mutation Progression in bones Progression in bones and lymph nodes Detection of ROS1 L2086F resistance mutation; undetectable F2004V clone H Crizotinib Entrectinib x 10 months x 34 months Undetectable L2086F and F2004V clones Lorlatinib monotherapy x 10 months Lorlatinib plus carboplatin/pemetrexed maintenance x 34 cycles Lorlatinib plus cabozantinib x 3 months Diagnosed with NSCLC, treated with ROS1-inhibitors Guardant360 identifies acquired, targetable alterations Guardant360 used throughout continuum of care to assess ctDNA at time of clinical progression From Guardant360 results, patient treated with combination therapy Assessment of ctDNA 6 weeks after treatment initiation showed likely molecular response GUARDANT™ Sakamoto et al. JCO PO, 2023. Jacob et al. 2021.https://doi.org/10.1016/j.heliyon.2020.e03841 INVESTOR 20 DAY 23 48 48

View entire presentation